Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Nakamura, Hisae ^a,b   Wang, Yuwei ^a   Kurita, Takeshi ^d   Adomat, Hans ^b   Cunha, Gerald R ^e   Wang, Yuzhuo ^a,b,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b VANCOUVER PROSTATE CENTRE   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENISTEIN; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MICROMETASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; ANIMAL; DISEASE COURSE; DRUG EFFECT; METABOLISM; METASTASIS; MOUSE MUTANT; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; XENOGRAFT;

ANIMALIA; MUS; RODENTIA;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DISEASE PROGRESSION; GENISTEIN; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 79956103053     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020034     Document Type: Article

References (58)

1. Quinn M, Babb P, (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90: 162-173.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
3. Setchell KD, Borriello SP, Hulme P, Kirk DN, Axelson M, (1984) Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr 40: 569-578.
4. Adlercreutz H, (1995) Phytoestrogens: epidemiology and a possible role in cancer protection. Environ Health Perspect 103 (Suppl 7): 103-112.
5. McCracken M, Olsen M, Chen MS Jr, Jemal A, Thun M, et al. (2007) Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 57: 190-205.
6. Haenszel W, Kurihara M, (1968) Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40: 43-68.
7. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, et al. (1991) Dietary effects on breast-cancer risk in Singapore. Lancet 337: 1197-1200.
8. Messina M, Barnes S, (1991) The role of soy products in reducing risk of cancer. J Natl Cancer Inst 83: 541-546.
9. Gallagher RP, Kutynec CL, (1997) Diet, micronutrients and prostate cancer: a review of the evidence. Can J Urol 4: 22-27.
10. Mills PK, Beeson WL, Phillips RL, Fraser GE, (1989) Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64: 598-604.
11. Adlercreutz H, Markkanen H, Watanabe S, (1993) Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342: 1209-1210.
12. Knight DC, Eden JA, (1996) A review of the clinical effects of phytoestrogens. Obstet Gynecol 87: 897-904.
13. Zava DT, Dollbaum CM, Blen M, (1998) Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med 217: 369-378.
14. Mayr U, Butsch A, Schneider S, (1992) Validation of two in vitro test systems for estrogenic activities with zearalenone, phytoestrogens and cereal extracts. Toxicology 74: 135-149.
15. Markiewicz L, Garey J, Adlercreutz H, Gurpide E, (1993) In vitro bioassays of non-steroidal phytoestrogens. J Steroid Biochem Mol Biol 45: 399-405.
16. Spinozzi F, Pagliacci MC, Migliorati G, Moraca R, Grignani F, et al. (1994) The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk Res 18: 431-439.
17. Davis JN, Singh B, Bhuiyan M, Sarkar FH, (1998) Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 32: 123-131.
18. Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, et al. (1998) Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer 31: 184-191.
19. Li Y, Bhuiyan M, Sarkar FH, (1999) Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int J Oncol 15: 525-533.
20. Alhasan SA, Pietrasczkiwicz H, Alonso MD, Ensley J, Sarkar FH, (1999) Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr Cancer 34: 12-19.
21. Lacroix H, Iglehart JD, Skinner MA, Kraus MH, (1989) Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 4: 145-151.
22. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, et al. (1994) c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54: 3260-3266.
23. Yu D, Matin A, Xia W, Sorgi F, Huang L, et al. (1995) Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene 11: 1383-1388.
24. Tan M, Yao J, Yu D, (1997) Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57: 1199-1205.
25. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, et al. (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595.
26. Hunter T, (1987) A thousand and one protein kinases. Cell 50: 823-829.
27. Ullrich A, Schlessinger J, (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212.
28. El Touny LH, Banerjee PP, (2009) Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res 69: 3695-3703.
29. Raffoul JJ, Banerjee S, Che M, Knoll ZE, Doerge DR, et al. (2007) Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. Int J Cancer 120: 2491-2498.
30. Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, et al. (2008) Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 68: 2024-2032.
31. Fischer L, Mahoney C, Jeffcoat AR, Koch MA, Thomas BE, et al. (2004) Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 48: 160-170.
32. Pendleton JM, Tan WW, Anai S, Chang M, Hou W, et al. (2008) Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 8: 132.
33. Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, et al. (2005) Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 64: 149-159.
34. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, et al. (2005) An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 85: 1392-1404.
35. Ohno S, Nakajima Y, Inoue K, Nakazawa H, Nakajin S, (2003) Genistein administration decreases serum corticosterone and testosterone levels in rats. Life Sci 74: 733-742.
36. Huggins C, Hodges CV, (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22: 232-240.
37. Feldman BJ, Feldman D, (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45.
38. Ryan CJ, Small EJ, (2005) Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol 23: 8225-8231.
39. Hillman GG, Wang Y, Che M, Raffoul JJ, Yudelev M, et al. (2007) Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model. BMC Cancer 7: 4.
40. Aronson WJ, Tymchuk CN, Elashoff RM, McBride WH, McLean C, et al. (1999) Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer 35: 130-136.
41. Cohen LA, Zhao Z, Pittman B, Scimeca J, (2003) Effect of soy protein isolate and conjugated linoleic acid on the growth of Dunning R-3327-AT-1 rat prostate tumors. Prostate 54: 169-180.
42. Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, et al. (2004) Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 3: 1271-1279.
43. Li Y, Che M, Bhagat S, Ellis KL, Kucuk O, et al. (2004) Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 6: 354-363.
44. Balabhadrapathruni S, Thomas TJ, Yurkow EJ, Amenta PS, Thomas T, (2000) Effects of genistein and structurally related phytoestrogens on cell cycle kinetics and apoptosis in MDA-MB-468 human breast cancer cells. Oncol Rep 7: 3-12.
45. Wang C, Kurzer MS, (1997) Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer 28: 236-247.
46. Martin PM, Horwitz KB, Ryan DS, McGuire WL, (1978) Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 103: 1860-1867.
47. Wang X, Clubbs EA, Bomser JA, (2006) Genistein modulates prostate epithelial cell proliferation via estrogen- and extracellular signal-regulated kinase-dependent pathways. J Nutr Biochem 17: 204-210.
48. Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, et al. (2006) Crosstalk between EGFR and extranuclear steroid receptors. Ann N Y Acad Sci 1089: 194-200.
49. Sithanandam G, Anderson LM, (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15: 413-448.
50. Larue L, Bellacosa A, (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24: 7443-7454.
51. Lee K, Kim J, Jeong KW, Lee KW, Lee Y, et al. (2009) Structure-based virtual screening of Src kinase inhibitors. Bioorg Med Chem 17: 3152-3161.
52. Lurje G, Lenz HJ, (2009) EGFR signaling and drug discovery. Oncology 77: 400-410.
53. Martin GS, (2003) Cell signaling and cancer. Cancer Cell 4: 167-174.
54. Takimoto CH, Glover K, Huang X, Hayes SA, Gallot L, et al. (2003) Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 12: 1213-1221.
55. Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, et al. Progesterone Is Essential for Maintenance and Growth of Uterine Leiomyoma. Endocrinology.
56. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, et al. (2000) Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19: 5406-5417.
57. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, et al. (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252-4263.
58. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, et al. (1999) Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 18: 4608-4618.